-
May 09, 2022Elpiscience Announces FDA IND Clearance of ES014, a First in Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors
ES014 is a first in class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the CD39-adenosine and TGF-β pathways.
-
May 06, 2022Positive Interim ES104 Phase 2 Data Reported in Combination with Paclitaxel in Biliary Tract Cancers
ES104 in combination with paclitaxel showed a high ORR including responses in all four BTC subtypes and good overall tolerability consistent with prior studies.
-
February 28, 2022Elpiscience Announces First Patient Dosed in Phase 1/2 Clinical Study of ES104 for Treatment of Colorectal Cancer
ES104 is currently the only clinical-stage bispecific antibody targeting VEGF and DLL4 in China.
-
February 11, 2022Elpiscience to Participate in Cross-Pacific Collaboration Panel at BIO CEO & Investor Conference
Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, toda...
-
February 09, 2022Elpiscience Announces CDE Clearance of IND Application for Anti-CD39 Monoclonal Antibody ES002
Elpiscience Biopharmaceuticals announced that the Center of Drug Evaluation (CDE) has cleared Elpiscience’s Investigational New Drug Application (IND) for ES002 to initiate a Phase I clinic
-
January 21, 2022Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors
Elpiscience Biopharmaceuticals announced that the first patient has been dosed in a U.S. multi-center, Phase I clinical trial.
